Hepatitis B and hepatocellular carcinoma

Hepatitis B Virus - The Cancer Culprit

• Primary Mechanism: Chronic inflammation from persistent HBV infection is the main driver of hepatocellular carcinoma (HCC).
• Viral Integration: HBV DNA integrates into the host genome, leading to genomic instability and activation of proto-oncogenes (e.g., MYC) or inactivation of tumor suppressors (e.g., p53).
• Key Viral Protein: HBx protein is a major contributor. It disrupts cell cycle control, inhibits apoptosis, and modulates signaling pathways.

⭐ High-Yield: The HBx protein is a transcriptional coactivator that interferes with the p53 tumor suppressor protein, crippling the cell's primary defense against malignant transformation.

Pathogenesis - From Hepatitis to Cancer

• Chronic inflammation from persistent HBV infection is the primary driver, leading to continuous liver regeneration and cirrhosis, a major risk factor.
• HBV DNA Integration:
  • Viral DNA integrates into the host genome, causing genomic instability.
  • Leads to insertional mutagenesis, activating proto-oncogenes or inactivating tumor suppressor genes like p53.
• Role of Viral Proteins:
  • The HBx protein is the main oncogenic factor.
  • It disrupts cell cycle regulation, inhibits apoptosis, and activates pro-growth signaling pathways (e.g., Wnt, NF-κB).
• Oxidative Stress:
  • Chronic inflammation and HBx activity generate reactive oxygen species (ROS), causing DNA damage.

⭐ Unlike Hepatitis C, HBV can cause hepatocellular carcinoma even in the absence of cirrhosis, primarily due to its direct oncogenic effects via DNA integration and HBx protein.

Clinical & Serology - Spotting the Enemy

• Presentation: Often asymptomatic for decades. Late signs mirror cirrhosis or liver failure: jaundice, ascites, hepatomegaly, RUQ pain.
• Progression Risk: ↑ with chronic infection, co-infection (HCV, HIV), alcohol, aflatoxin B1 exposure.

Prevention & Management - Guarding the Liver

• Primary Prevention: Universal HBV vaccination series is key. Screen pregnant women & blood products.
• Chronic HBV Management: Antiviral therapy (e.g., Tenofovir, Entecavir) to suppress HBV DNA replication & reduce liver inflammation.
• HCC Surveillance: For patients with cirrhosis or high-risk features, perform liver ultrasound (US) every 6 months, with or without alpha-fetoprotein (AFP).

⭐ Antiviral therapy significantly ↓ HCC risk, but does not eliminate it. Surveillance must continue even in patients with undetectable HBV DNA.

High‑Yield Points - ⚡ Biggest Takeaways

• Hepatitis B (HBV), a DNA hepadnavirus, is a major cause of hepatocellular carcinoma (HCC) worldwide.
• Primary mechanism: Integration of viral DNA into the host genome, leading to genomic instability.
• The viral HBx protein is a key oncoprotein that disrupts cell cycle regulation by inhibiting p53.
• Chronic inflammation from persistent infection is a major driver of carcinogenesis, typically through cirrhosis.
• Prevention with the HBV vaccine is the most effective measure against HBV-induced HCC.